Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
Type:
Grant
Filed:
October 5, 2021
Date of Patent:
July 2, 2024
Assignees:
THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., Instituto Carlos Slim de la Salud, A.C.
Inventors:
Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
Abstract: Exemplary embodiments of the present invention relate to a combination formulation for treatment or enhancing the therapy of liver disease, and more particularly, to a combination formulation prepared by containing colchicine and metformin as main active ingredients. The composition according to exemplary embodiments of the present invention may be used as an effective therapeutic agent for liver disease capable of treating and preventing liver fibrosis, liver cirrhosis, liver cancer, or hepatitis by reducing the amount of fat accumulated in the liver tissues by a synergistic effect of colchicine and metformin and lowering glucose tolerance and insulin tolerance and further, may be used as an excellent drug capable of replacing ursodeoxycholic acid.
Abstract: The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.
Type:
Grant
Filed:
December 31, 2017
Date of Patent:
June 4, 2024
Assignee:
Hangzhou DAC Biotech Co., Ltd.
Inventors:
Robert Yongxin Zhao, Qingliang Yang, Yuanyuan Huang, Linyao Zhao, Shun Gai, Hangbo Ye, Jun Lei, Yifang Xu, Mingjun Cao, Huihui Guo, Junxiang Jia, Qianqian Tong, Wenjun Li, Xiaomai Zhou, Hongsheng Xie, Lu Bai, Xiang Cai, Xiaotao Zhuo, Xiuzheng Zhang, Jun Zheng
Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
Abstract: Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.
Type:
Grant
Filed:
August 12, 2022
Date of Patent:
April 23, 2024
Assignees:
Southwest Research Institute, The Government of the United States, as represented by The Secretary of the Army, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Jonathan A. Bohmann, Nadean M. Gutierrez, Joseph A. Mcdonough, Robert Francis Campbell, Michael Gordon Joyce, Rekha Panchal, Rajeshwer Sankhala, Allen Duplantier
Abstract: The present invention relates to 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives and derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol as new compounds. The subject of the invention is the medical use of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives and the medical use of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol derivatives. The subject of the invention is the use of new compounds as an agent with the properties of a steroid sulfatase inhibitor and/or an estrogen receptor modulator. The present invention relates to the medical use of novel compounds for use as an antimicrobial medicament and/or estrogen receptor modulator. In particular, 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives are for use as medicament in cancer therapy.
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
March 26, 2024
Assignee:
Politechnika Gdanska
Inventors:
Sebastian Demkowicz, Mateusz Dasko, Janusz Rachon
Abstract: The present invention relates to a crystal form I of tenvermectin B, which can be characterized by X-ray powder diffraction (XRPD) pattern, Infrared (IR) absorption spectrum, Differential scanning calorimetry (DSC) thermogram and the like. Meanwhile, the present invention also relates to a method for preparing the crystal form I of tenvermectin B and a use thereof.
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Grant
Filed:
January 13, 2022
Date of Patent:
February 27, 2024
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
Abstract: The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.
Abstract: This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 ?g/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
February 6, 2024
Assignee:
Corcept Therapeutics, Inc.
Inventors:
Andreas G. Moraitis, Pejman Cohan, Joseph K. Belanoff
Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.
Type:
Grant
Filed:
August 25, 2022
Date of Patent:
January 30, 2024
Assignee:
LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
Inventors:
Keshan Zhang, Haixue Zheng, Huimei Cui, Bo Yang, Hong Tian, Zixiang Zhu, Tao Feng, Fan Yang, Weijun Cao, Xusheng Ma, Yi Ru, Jianhong Guo, Xiangtao Liu
Abstract: This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
Type:
Grant
Filed:
June 15, 2021
Date of Patent:
January 9, 2024
Assignee:
TherapeuticsMD, Inc.
Inventors:
Janice Cacace, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Frederick Sancilio, Julia Amadio, Brian Bernick, Neda Irani
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
January 9, 2024
Assignee:
Pfizer Inc.
Inventors:
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
December 26, 2023
Assignee:
DR. FALK PHARMA GMBH
Inventors:
Markus Pröls, Roland Greinwald, Michael Trauner, Peter Fickert
Abstract: The present invention addresses the problem of providing a pharmaceutical composition for treatment of a variety of conditions accompanied by renal dysfunction. Renal dysfunction is improved by a pharmaceutical composition that comprises an optical isomer of a 1,4-benzothiazepine-1-oxide derivative represented by general formula [II] wherein, R represents a hydrogen atom or a hydroxyl group, and “*” indicates being an optical isomer. or a pharmacologically acceptable salt thereof.
Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.